Thyroid disorders are the most frequent endocrine adverse reactions, being more often related to anti-PD-1 therapy (up to 40%), and are almost the only endocrine side effect of anti-PD-L1 (6–11%), compared to anti-CTLA-4 (5% of cases) [10,48]. This evidence concerns the gene CD274 and thyroid gland disorder.